Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients-authors' response

Tzong-Yow Wu¹, Pao-Yu Chen^{1

2}, Jann-Tay Wang^{1

3}, Wang-Da Liu⁴, Yee-Chun Chen^{1

3

5}, Shan-Chwen Chang^{1

5}

Affiliations

¹ Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
² Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.
³ National Institutes of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan, Taiwan.
⁴ Department of Internal Medicine, National Taiwan University Cancer Center, Taipei, Taiwan.
⁵ School of Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.

Editorial

Tzong-Yow Wu et al. J Antimicrob Chemother. 2024.

. 2024 Dec 2;79(12):3360-3361.

doi: 10.1093/jac/dkae357.

Tzong-Yow Wu¹, Pao-Yu Chen^{1

2}, Jann-Tay Wang^{1

3}, Wang-Da Liu⁴, Yee-Chun Chen^{1

3

5}, Shan-Chwen Chang^{1

5}

¹ Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
² Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.
³ National Institutes of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan, Taiwan.
⁴ Department of Internal Medicine, National Taiwan University Cancer Center, Taipei, Taiwan.
⁵ School of Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.

No abstract available

Comment on

Comment on: Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients.
Barone F, Giacomelli A, Casalini G, Corbellino M, Lai A, Gori A, Antinori S. Barone F, et al. J Antimicrob Chemother. 2024 Sep 3;79(9):2400-2402. doi: 10.1093/jac/dkae234. J Antimicrob Chemother. 2024. PMID: 39073825 No abstract available.